Respiratory Syncytial Virus RSV Vaccine
Whereas in 2024, the availability of Arexvy, a vaccine approved by Health Canada in August for adults aged 60 and over, marks a significant milestone in protecting older adults against the respiratory syncytial virus RSV; And whereas Arexvy has demonstrated nearly 83 per cent efficacy in preventing lower respiratory tract disease caused by RSV and a 94 per cent efficacy in preventing severe RSV-associated illness, according to the FDAs analysis of data; And whereas the authorization of Arexvy for use in Canada addresses the critical need for preventing RSV in older adults, who may face gr